Background: New neural antibodies are being identified each year and determining how to measure them and how to interpret test results is complex. In addition, screening with two methods is recommended for most antibodies, particularly paraneoplastic antibodies. We report the clinical validation and profile of a series of neural autoantibodies detected with a comprehensive testing algorithm. Methods: This is an ongoing study in which we are asking for the clinical correlation and final diagnosis of patients whose serum and/or CSF samples were tested at the BC Neuroimmunology Lab, Vancouver for neural autoantibodies. We performed immunofluorescence screening assay/IHC in rat brain sections in combination with confirmatory fixed or live Cell-Based assays and/or immunoblots. Results: We obtained clinical information from 219 samples (22 positive), Upon clinical inquiry, we obtained clinical information on 12 cases (five positive and seven negative). One Ttitin positive case was associated with anti-acetylcholine receptor antibody myasthenia and one Zic4 antibody was detected as a false positive by immunoblot but was negative by Rat Brain IHC. Conclusions: We have identified 10 percent seropositivity on 219 samples testing for Mosai-6 and full paraneoplastic testing. Further clinical validation studies are ongoing to evaluate the accuracy of our serological testing for neural antibodies.